Exact Sciences Corporation

    Jurisdiction
    United States
    LEI
    549300VM3X1FYD4N9Z14
    ISIN
    US30063P1057 (EXAS)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    InsiderPie Expert Score
    55 / 100
    Even with peer group:
    57 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €2.51B
    Gross margin
    68.2%
    EBIT
    -€860.63M
    EBIT margin
    -34.3%
    Net income
    -€857.40M
    Net margin
    -34.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €3.03B +20.9% €59.99M -107.0%
    €3.40B +12.2% €201.22M +235.4%
    €3.71B +9.0% €257.59M +28.0%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Doyle James Edward N/A -1.5K $42.02 -$62.40K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Nancy Zevenbergen 1M $54.11M -150K Sell
    James Anderson 833K $36.04M -180K Sell
    Peter Brown 34K $1.47M -31K Sell

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications